Compare PAX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | IMCR |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | Cayman Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.7B |
| IPO Year | 2021 | 2021 |
| Metric | PAX | IMCR |
|---|---|---|
| Price | $15.97 | $36.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | ★ 482.9K | 276.8K |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.48% | N/A |
| EPS Growth | ★ 58.69 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $405,792,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | $21.37 | $10.50 |
| P/E Ratio | $24.02 | ★ N/A |
| Revenue Growth | 23.45 | ★ 28.11 |
| 52 Week Low | $9.43 | $23.15 |
| 52 Week High | $16.47 | $40.72 |
| Indicator | PAX | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 50.52 |
| Support Level | $15.43 | $35.41 |
| Resistance Level | $15.80 | $37.17 |
| Average True Range (ATR) | 0.38 | 1.71 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 60.77 | 24.54 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.